Last updated: 18 June 2019 at 4:31am EST

Supratim Bose Net Worth

The estimated Net Worth of Supratim Bose is at least $39 Million dollars as of 3 October 2017. Supratim Bose owns over 347,137 units of Boston Scientific stock worth over $39,033,306 and over the last 13 years Supratim sold BSX stock worth over $0.

Supratim Bose BSX stock SEC Form 4 insiders trading

Supratim has made over 24 trades of the Boston Scientific stock since 2013, according to the Form 4 filled with the SEC. Most recently Supratim exercised 347,137 units of BSX stock worth $2,516,743 on 3 October 2017.

The largest trade Supratim's ever made was exercising 347,137 units of Boston Scientific stock on 3 October 2017 worth over $2,516,743. On average, Supratim trades about 18,683 units every 58 days since 2012. As of 3 October 2017 Supratim still owns at least 470,621 units of Boston Scientific stock.

You can see the complete history of Supratim Bose stock trades at the bottom of the page.

What's Supratim Bose's mailing address?

Supratim's mailing address filed with the SEC is 11A COOLING CLOSE, , SINGAPORE, U0, 558176.

Insiders trading at Boston Scientific

Over the last 20 years, insiders at Boston Scientific have traded over $938,841,783 worth of Boston Scientific stock and bought 1,398,972 units worth $16,231,539 . The most active insiders traders include Peter M Nicholas, John E Abele, and Michael F Mahoney. On average, Boston Scientific executives and independent directors trade stock every 3 days with the average trade being worth of $4,899,929. The most recent stock trade was executed by Michael F Mahoney on 5 September 2024, trading 162,777 units of BSX stock currently worth $13,212,609.

What does Boston Scientific do?

Boston Scientific Corp. engages in the development, manufacture and marketing of medical devices that are used in interventional medical procedures. It operates through the MedSurg and Cardiovascular segments.

Complete history of Supratim Bose stock trades at Boston Scientific

Insider	Trans. Transaction	Total value
Supratim Bose EVP, President, and Asia-Pacific	Option	$2,516,743 3 Oct 2017
Supratim Bose EVP, President, and Asia-Pacific	Option	$166,105 28 Feb 2017
Supratim Bose EVP, President, and Asia-Pacific	Option	$166,105 28 Feb 2017
Supratim Bose EVP, President, and Asia-Pacific	Option	$79,020 27 Feb 2017
Supratim Bose EVP, President, and Asia-Pacific	Option	$79,020 27 Feb 2017
Supratim Bose EVP, President, and Asia-Pacific	Option	$66,311 24 Feb 2017
Supratim Bose EVP, President, and Asia-Pacific	Option	$66,311 24 Feb 2017
Supratim Bose EVP, President, and Asia-Pacific	Option	$52,534 23 Feb 2017
Supratim Bose EVP, President, and Asia-Pacific	Option	$54,648 22 Feb 2017
Supratim Bose EVP, President, and Asia-Pacific	Option	$326,581 3 Jan 2017
Supratim Bose EVP, President, and Asia-Pacific	Option	$294,579 1 Jan 2017
Supratim Bose EVP, President, and Asia-Pacific	Option	$171,257 27 Feb 2016
Supratim Bose EVP, President, and Asia-Pacific	Option	$46,375 24 Feb 2016
Supratim Bose EVP, President, and Asia-Pacific	Option	$36,980 23 Feb 2016
Supratim Bose EVP, President, and Asia-Pacific	Option	$907,764 1 Jan 2016
Supratim Bose EVP, President, and Asia-Pacific	Option	$168,172 27 Feb 2015
Supratim Bose EVP, President, and Asia-Pacific	Option	$44,459 24 Feb 2015
Supratim Bose EVP, President, and Asia-Pacific	Option	$197,309 3 Jan 2015
Supratim Bose EVP, President, and Asia-Pacific	Option	$274,288 1 Jan 2015
Supratim Bose EVP, President, and Asia-Pacific	Option	$88,622 28 Feb 2014
Supratim Bose EVP, President, and Asia-Pacific	Option	$42,361 27 Feb 2014
Supratim Bose EVP, President, and Asia-Pacific	Option	$178,055 3 Jan 2014
Supratim Bose EVP, President, and Asia-Pacific	Option	$23,339 27 Feb 2013
Supratim Bose EVP, President, and Asia-Pacific	Option	$88,804 3 Jan 2013

Boston Scientific executives and stock owners

Boston Scientific executives and other stock owners filed with the SEC include:

Michael Mahoney,
Chairman of the Board, President, Chief Executive Officer
Daniel Brennan,
Chief Financial Officer, Executive Vice President
Joseph Fitzgerald,
Executive Vice President, President, Interventional Cardiology
Edward Mackey,
Executive Vice President - Operations
David Pierce,
Executive Vice President and President, MedSurg and President, Endoscopy
Michael F. Mahoney,
Chairman, Pres & CEO
Daniel J. Brennan,
Exec. VP & CFO
Joseph M. Fitzgerald,
Exec. VP & Pres of Interventional Cardiology
Edward F. Mackey,
Exec. VP of Global Operations
Jeffrey B. Mirviss,
Exec. VP & Pres of Peripheral Interventions
Edward Ludwig,
Lead Independent Director
Charles Dockendorff,
Independent Director
David Roux,
Independent Director
John Sununu,
Independent Director
Donna James,
Independent Director
Nelda Connors,
Independent Director
Ellen Zane,
Independent Director
Stephen MacMillan,
Independent Director
Yoshiaki Fujimori,
Independent Director
John Sorenson,
Senior Vice President - Manufacturing and Supply Chain
Meghan Scanlon,
Senior Vice President and President, Urology and Pelvic Health
Scott Olson,
Senior Vice President and President, Rhythm Management
Maulik Nanavaty,
Senior Vice President and President - Neuromodulation
Wendy Carruthers,
Senior Vice President - Human Resources
Desiree Ralls-Morrison,
Senior Vice President, General Counsel, Corporate Secretary
Jodi Eddy,
Senior Vice President, Chief Information Officer
Eric Thepaut,
Executive Vice President and President - Europe, Middle East and Africa
Jeffrey Mirviss,
Executive Vice President and President - Peripheral Interventions
Ian Meredith,
Executive Vice President, Global Chief Medical Officer
Arthur Butcher,
Executive Vice President and President, Asia Pacific
Catherine Jennings,
VP of Global Marketing & New Bus. Devel. of Peripheral Interventions
Vance R. Brown,
Sr. VP, Gen. Counsel & Corp. Sec.
Susan Vissers Lisa,
VP of Investor Relations
Jodi Euerle Eddy,
Sr. VP and Chief Information & Digital Officer
Jonathan R Monson,
VP, Global Controller & Chief Accounting Officer
Vance R Brown,
SVP, GC and Corp. Secretary
Timothy A. Pratt,
EVP & General Counsel
Supratim Bose,
EVP & President, Asia-Pacific
Michael P. Phalen,
SVP & President, Endoscopy
Keith D Dawkins,
Sr. VP, Chief Medical Officer
Kevin J. Ballinger,
EVP & Pres, Interven Cardio
Cheryl Pegus,
Director
David S Wichmann,
Director
Xin Warren Wang,
SVP and Pres, Asia Pacific
Peter M Nicholas,
Director
Kristina M Johnson,
Director
Nicholas J Jr Nicholas,
Director
Karen Prange,
SVP&Pres, Uro & Women's Health
Ernest Mario,
Director
John E Abele,
Director
Uwe E Reinhardt,
Director
Katharine T Bartlett,
Director
Jean Fitterer Lance,
SVP & Chief Compliance Officer
Kenneth Pucel,
EVP, Operations
Bruce L Byrnes,
Director
John Michael Onuscheck,
SVP & Pres-Neuromodulation
Jeffrey D Capello,
Chief Accounting Officer
Otha T. Iii Spriggs,
SVP, Human Resources
William Kucheman,
SVP & Group President
John Raymond Elliott,
Director
Lawrence R Neumann,
SVP and Pres, Emerging Markets
John B. Pedersen,
Pres,Uro & Women's Health
Brian R Burns,
SVP - Quality
Ray J Groves,
Director
Sam R Leno,
CFO & EVP Finance & IS
Stephen F Moreci,
Sr. VP, Endosurgery
Marye Anne Fox,
Director
Fred Colen,
EVP
John E Pepper,
Director
James Gilbert,
EVP
Donovan Paul,
SVP, Corporate Comm
David W Mc Faul,
Senior VP International
Ursula M Burns,
Director
Warren B Rudman,
Director
William F Jr Mcconnell,
SVP, Administration CRM
Donald S Baim,
EVP, Chief Med. & Sci. Officer
Lucia Luce Quinn,
Exec. Vice President-HR
James R Tobin,
President & CEO
Paul W Sandman,
EVP and General Counsel
Paul A Laviolette,
COO
Nancy Ann Deparle,
Director
Joel Lawrence Fleishman,
Director
David C Habiger,
Director
Jonathan Monson,
SVP, Global Controller and CAO
Emily Woodworth,
SVP, Global Controller and CAO
Jessica L Mega,
Director
Susan E Morano,
Director